• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did NewAmsterdam Pharma’s (NAMS) Sharp Revenue Drop and Wider Loss Just Shift Its Investment Narrative?

    Simply Wall St·08/11/2026 11:24:21
    Listen to the news
    • In the past quarter, NewAmsterdam Pharma Company N.V. reported second-quarter 2026 results showing sales of US$3.7 million versus US$19.15 million a year earlier, alongside a net loss of US$64.14 million compared with US$17.36 million previously.
    • The widening basic loss per share from continuing operations, rising to US$0.52 from US$0.15, highlights mounting cost pressures against a shrinking revenue base.
    • Next, we’ll examine how the sharp year-on-year revenue drop and much larger net loss shape NewAmsterdam Pharma’s investment narrative for investors.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    What Is NewAmsterdam Pharma's Investment Narrative?

    To own NewAmsterdam Pharma today, you need to believe that obicetrapib’s cardiovascular and potential Alzheimer’s applications can ultimately justify prolonged losses and dilution risk. The recent CHMP positive opinion for Ubeslo and Evlarco keeps the European regulatory catalyst intact, but the Q2 2026 results complicate the near-term picture: revenue has dropped sharply while the net loss has widened, even as the share price has fallen around 20% over the past month. That mix suggests the upcoming EC decision, Menarini launch execution and visibility on milestone timing matter even more now, because the company’s shrinking top line and higher burn increase dependence on external funding and partnership economics. In short, the science and European regulatory progress are advancing, but the financial strain is becoming harder to ignore.

    However, one funding-related risk in particular could catch shareholders off guard. NewAmsterdam Pharma's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

    Exploring Other Perspectives

    NAMS 1-Year Stock Price Chart
    NAMS 1-Year Stock Price Chart
    The Simply Wall St Community’s three fair value estimates span from around US$51 to a very large figure above US$1 billion, reflecting sharply different expectations. Set against the latest steep revenue decline and expanding losses, that spread shows how differently people weigh European obicetrapib approvals versus balance sheet pressure, making it worth exploring several viewpoints before forming your own.

    Explore 3 other fair value estimates on NewAmsterdam Pharma - why the stock might be a potential multi-bagger!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free NewAmsterdam Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

    Seeking Other Investments?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.